Meta-Analysis

Osteoporosis Drugs Show Similar Outcomes

This overview of systematic reviews with meta-analyses found broadly similar efficacy and safety outcomes for romosozumab compared with teriparatide in postmenopausal osteoporosis. Because the quality of evidence ranged from very low to moderate, treatment selection should remain individualized around fracture risk, cardiovascular history, and clinician guidance.